In the BioHarmony Drug Report Database

Zydelig (idelalisib) is a small molecule pharmaceutical. Idelalisib was first approved as Zydelig on 2014-07-23. It is used to treat lymphoid leukemia and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia and non-hodgkin lymphoma. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. In addition, it is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. Zydelig’s patents are valid until 2033-09-02 (FDA).